Uniwersytet Jagiellonski Collegium Medicum;Neurolixis
发明人:
Anna WESOLOWSKA,Magdalena JASTRZEBSKA-WIESEK,Adrian NEWMAN-TANCREDI,Mark Andrew VARNEY
申请号：
US16630938
公开号：
US20200155535A1
申请日:
2018.07.20
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to the reduction of the side-effects induced by tetrabenazine or other inhibitors of vesicular monoamine transporter (VMAT), in the treatment of central nervous system disorders such as Huntington's disease, L-DOPA-induced dyskinesias in Parkinson's disease, Tourette's syndrome or tardive dyskinesia. The invention comprises administering to a patient in need thereof an effective amount of activates selective serotonin 5-IIT1A receptors agonist, whereby the side-effects of depression or Parkinsonism induced by tetrabenazine or other VMAT inhibitors are minimized
